180 related articles for article (PubMed ID: 24327695)
1. Personalized therapy for acute myeloid leukemia.
Hourigan CS; Karp JE
Cancer Discov; 2013 Dec; 3(12):1336-8. PubMed ID: 24327695
[TBL] [Abstract][Full Text] [Related]
2. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
[TBL] [Abstract][Full Text] [Related]
3. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
Lam SS; He AB; Leung AY
Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
[TBL] [Abstract][Full Text] [Related]
5. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
Lee SI; Celik S; Logsdon BA; Lundberg SM; Martins TJ; Oehler VG; Estey EH; Miller CP; Chien S; Dai J; Saxena A; Blau CA; Becker PS
Nat Commun; 2018 Jan; 9(1):42. PubMed ID: 29298978
[TBL] [Abstract][Full Text] [Related]
6. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
Collignon A; Hospital MA; Montersino C; Courtier F; Charbonnier A; Saillard C; D'Incan E; Mohty B; Guille A; Adelaïde J; Carbuccia N; Garnier S; Mozziconacci MJ; Zemmour C; Pakradouni J; Restouin A; Castellano R; Chaffanet M; Birnbaum D; Collette Y; Vey N
Blood Cancer J; 2020 Jun; 10(6):64. PubMed ID: 32488055
[TBL] [Abstract][Full Text] [Related]
7. Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling.
Bhatt VR
Cancer Treat Rev; 2019 May; 75():52-61. PubMed ID: 31003190
[TBL] [Abstract][Full Text] [Related]
8. The rocky road to personalized medicine in acute myeloid leukaemia.
Brinda B; Khan I; Parkin B; Konig H
J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine for acute myeloid leukemia.
Lai C; Karp JE; Hourigan CS
Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
[TBL] [Abstract][Full Text] [Related]
10. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.
Bret C; Viziteu E; Kassambara A; Moreaux J
Expert Rev Hematol; 2016; 9(4):351-60. PubMed ID: 26761438
[TBL] [Abstract][Full Text] [Related]
11. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
[TBL] [Abstract][Full Text] [Related]
12. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
[No Abstract] [Full Text] [Related]
13. Acute Myeloid Leukemia: Changing Treatment Paradigms and Novel Agents in Development.
Konig H; Zeidner JF
Curr Cancer Drug Targets; 2020; 20(7):471-472. PubMed ID: 32703130
[No Abstract] [Full Text] [Related]
14. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
Swords RT; Azzam D; Al-Ali H; Lohse I; Volmar CH; Watts JM; Perez A; Rodriguez A; Vargas F; Elias R; Vega F; Zelent A; Brothers SP; Abbasi T; Trent J; Rangwala S; Deutsch Y; Conneally E; Drusbosky L; Cogle CR; Wahlestedt C
Leuk Res; 2018 Jan; 64():34-41. PubMed ID: 29175379
[TBL] [Abstract][Full Text] [Related]
15. New drugs for acute myeloid leukemia inspired by genomics and when to use them.
Pollyea DA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):45-50. PubMed ID: 30504290
[TBL] [Abstract][Full Text] [Related]
16. Precision therapy for acute myeloid leukemia.
Yang X; Wang J
J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
[TBL] [Abstract][Full Text] [Related]
17. In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene.
Such E; Cordón L; Sempere A; Villamón E; Ibañez M; Luna I; Gómez-Seguí I; López-Pavía M; Alonso C; Lo-Coco F; Cervera J; Sanz MA
Ann Hematol; 2014 Nov; 93(11):1931-3. PubMed ID: 24728721
[No Abstract] [Full Text] [Related]
18. Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.
Benard BA; Leak LB; Azizi A; Thomas D; Gentles AJ; Majeti R
Nat Commun; 2021 Dec; 12(1):7244. PubMed ID: 34903734
[TBL] [Abstract][Full Text] [Related]
19. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
Grunwald MR; Levis MJ
Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
[TBL] [Abstract][Full Text] [Related]
20. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
Bhatla T; Jones CL; Meyer JA; Vitanza NA; Raetz EA; Carroll WL
J Pediatr Hematol Oncol; 2014 Aug; 36(6):413-8. PubMed ID: 24942023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
